Sanofi, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on the stock and has a €115.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sachin Jain has given his Buy rating due to a combination of factors including Sanofi’s strong financial performance and future growth potential. The company reported an 8% earnings per share (EPS) beat in the third quarter of 2025, driven by a 2% sales increase, with notable contributions from key products like Dupixent and Lantus. This robust performance has led to an unchanged full-year 2025 guidance, indicating confidence in sustained profitability.
Additionally, Sanofi’s pipeline, although facing some setbacks, still holds promise with potential growth drivers such as tolebrutinib and amlitelimab. Despite limited immediate pipeline catalysts, the valuation remains attractive with a projected 13% compound annual growth rate (CAGR) in EPS over the next three years. The current price-to-earnings ratio of approximately 10x for 2026 earnings further underscores the stock’s undervaluation relative to its growth prospects.
In another report released today, Bernstein also maintained a Buy rating on the stock with a €119.00 price target.